Jennifer Ely, DO
Pulmonary Disease · Lansing, MINPI 1467422618
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Mylan Specialty L.p. at 43.1% of the total. Reporting peaked in 2019 at $12,532 and has fallen 83.5% since, to $2,073 in 2025. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 588 payments — averaging $57.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$14K
- Grifols USA, LLC$10K
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- GSK$925
- Jazz Pharmaceuticals Inc.$650
- plus $3K from 32 others
Across 6 payments — averaging $612.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Therapeutics LLC$4K
What the payments were for
- Consulting fees$1,7895%
- Speaking & faculty fees$18,63455%
- Travel & lodging$1,9806%
- Food & beverage$10,56131%
- Education$6252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$13,776
- Prolastin-C Liquid$7,715
- Prolastin-C$1,420
- TEZSPIRE$223
- FASENRA$223
- AIRSUPRA$119
- BREZTRI$104
How this compares
$33,590 in reported general payments places this provider in the 90th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 27 | $333,606 |
| AdempasRiociguat | 24 | $329,049 |
| Bosentan | 13 | $106,058 |
| Dupixent PenDupilumab | 22 | $78,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $70,469 |
| XolairOmalizumab | 11 | $62,621 |
| Fasenra PenBenralizumab | 12 | $61,169 |
| Dupixent SyringeDupilumab | 13 | $48,647 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $40,633 |
| Spiriva RespimatTiotropium Bromide | 25 | $29,786 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $21,249 |
| Spiriva HandihalerTiotropium Bromide | 19 | $18,675 |
| Qvar RedihalerBeclomethasone Dipropionate | 35 | $14,954 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $13,013 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $10,455 | $333,60627 claims |
| BayerAdempas | $57 | $329,04924 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $925 | $111,102136 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $395 | $106,05813 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,633 | $58,14675 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,238 | $20,05244 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $29 | $14,95435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Lansing
- David YoungLansing$36K
- Michael MasnyjLansing$16K
- Corey ObrienLansing$15K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.